About the BIO Asia International Conference
The BIO Asia International Conference in Tokyo brings together the global biotechnology and pharmaceutical industry to explore licensing collaborations and investor engagement in the current Asia-Pacific business and policy environments. Gain insights into the changes, challenges, and opportunities key opinion and policy leaders foresee for the Japanese biotech market and throughout the region. Companies with more than 460 therapeutic assets from more than 25 countries pursued Partnering discussions at the 2019 Tokyo conference.
Assets by Therapeutic Area
Gynecology and obstetrics
|Increase Since Last Update
*as of February 14, 2020
Meet the venture capital and private equity investors focused on cross-border biotechnology development who are currently active in the partnering system and ready to meet.
Aceras Life Sciences | Asset Management Ventures | BioInnovation Capital | Chaperone Investment | Eight Roads Ventures | Japan First Republic Bank | Hannol Ventures | Harbin Pharma | JAFCO Mitsubishi UFJ Capital | Mitsui Global Investment | Momentum Biotech | MSQ Ventures | Otsuka Pharmacautical Co. | Premir Partners | Shinsei Capital Partners | W Global Capital